Skip to content
Business
Prognosis

Pfizer, BioNTech Submit Initial Data for Shot in Young U.S. Kids

  • Companies expect formal FDA application in coming weeks
  • Tuesday’s statement includes no new new results from trial
    
Photographer: Angus Mordant/Bloomberg

Pfizer Inc. and partner BioNTech SE said they have submitted initial data to U.S. regulators about the use of their Covid-19 vaccine in children ages 5 to 11, one step closer to bringing shots to school-age kids.

The companies said in a statement that they expect to make a formal request for emergency authorization in the coming weeks. Submissions to regulators in Europe and elsewhere are also planned.